docetaxel + cisplatin + oteracil potassium

This is a combination chemotherapy regimen consisting of three drugs: - **Docetaxel** is a taxane-class antineoplastic agent that promotes and stabilizes microtubule assembly, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells. - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to DNA damage and apoptosis in cancer cells. - **Oteracil potassium** is typically used as part of the oral fluoropyrimidine S-1 (which also contains tegafur and gimeracil); oteracil potassium inhibits the phosphorylation of 5-fluorouracil (5-FU) in the gastrointestinal tract, reducing GI toxicity. This specific triple-drug combination has been investigated primarily for advanced gastric cancer as perioperative or adjuvant chemotherapy. The rationale for combining these agents lies in their complementary mechanisms—docetaxel disrupts microtubules, cisplatin damages DNA, and oteracil potassium (as part of S-1) modulates 5-FU activity to enhance efficacy while minimizing GI side effects[1][2].